173 related articles for article (PubMed ID: 28968963)
1. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma.
Kumar SS; Sengupta S; Lee K; Hura N; Fuller C; DeWire M; Stevenson CB; Fouladi M; Drissi R
Oncotarget; 2017 Sep; 8(38):62962-62975. PubMed ID: 28968963
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation.
Senthil Kumar S; Sengupta S; Zhu X; Mishra DK; Phoenix T; Dyer L; Fuller C; Stevenson CB; DeWire M; Fouladi M; Drissi R
Mol Cancer Res; 2020 Nov; 18(11):1711-1723. PubMed ID: 32801164
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
4. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
5. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
[TBL] [Abstract][Full Text] [Related]
6.
Kluiver TA; Alieva M; van Vuurden DG; Wehrens EJ; Rios AC
Front Oncol; 2020; 10():92. PubMed ID: 32117746
[TBL] [Abstract][Full Text] [Related]
7. Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition.
Taylor IC; Hütt-Cabezas M; Brandt WD; Kambhampati M; Nazarian J; Chang HT; Warren KE; Eberhart CG; Raabe EH
J Neuropathol Exp Neurol; 2015 Aug; 74(8):778-90. PubMed ID: 26115193
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
[TBL] [Abstract][Full Text] [Related]
9. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
[TBL] [Abstract][Full Text] [Related]
10. STAT3 is a key molecule in the oncogenic behavior of diffuse intrinsic pontine glioma.
Park J; Lee W; Yun S; Kim SP; Kim KH; Kim JI; Kim SK; Wang KC; Lee JY
Oncol Lett; 2020 Aug; 20(2):1989-1998. PubMed ID: 32724445
[TBL] [Abstract][Full Text] [Related]
11. Genomic Insights into Diffuse Intrinsic Pontine Glioma.
Lapin DH; Tsoli M; Ziegler DS
Front Oncol; 2017; 7():57. PubMed ID: 28401062
[TBL] [Abstract][Full Text] [Related]
12. Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.
Misuraca KL; Cordero FJ; Becher OJ
Front Oncol; 2015; 5():172. PubMed ID: 26258075
[TBL] [Abstract][Full Text] [Related]
13. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
Asby DJ; Killick-Cole CL; Boulter LJ; Singleton WG; Asby CA; Wyatt MJ; Barua NU; Bienemann AS; Gill SS
Cancer Manag Res; 2018; 10():3483-3500. PubMed ID: 30254491
[TBL] [Abstract][Full Text] [Related]
14. Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG).
Dai L; Chen J; Lin Z; Wang Z; Mu S; Qin Z
J Cancer; 2020; 11(16):4683-4691. PubMed ID: 32626514
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.
Xu C; Liu X; Geng Y; Bai Q; Pan C; Sun Y; Chen X; Yu H; Wu Y; Zhang P; Wu W; Wang Y; Wu Z; Zhang J; Wang Z; Yang R; Lewis J; Bigner D; Zhao F; He Y; Yan H; Shen Q; Zhang L
Oncotarget; 2017 Sep; 8(44):76644-76655. PubMed ID: 29100338
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.
Monje M; Mitra SS; Freret ME; Raveh TB; Kim J; Masek M; Attema JL; Li G; Haddix T; Edwards MS; Fisher PG; Weissman IL; Rowitch DH; Vogel H; Wong AJ; Beachy PA
Proc Natl Acad Sci U S A; 2011 Mar; 108(11):4453-8. PubMed ID: 21368213
[TBL] [Abstract][Full Text] [Related]
17. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands.
Veldhuijzen van Zanten SE; Jansen MH; Sanchez Aliaga E; van Vuurden DG; Vandertop WP; Kaspers GJ
Expert Rev Anticancer Ther; 2015 Feb; 15(2):157-64. PubMed ID: 25435089
[TBL] [Abstract][Full Text] [Related]
18. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).
Bailey CP; Figueroa M; Mohiuddin S; Zaky W; Chandra J
Bioengineering (Basel); 2018 Oct; 5(4):. PubMed ID: 30340362
[TBL] [Abstract][Full Text] [Related]
19. Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Meel MH; Sewing ACP; Waranecki P; Metselaar DS; Wedekind LE; Koster J; van Vuurden DG; Kaspers GJL; Hulleman E
Exp Cell Res; 2017 Nov; 360(2):397-403. PubMed ID: 28947132
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma.
Yadavilli S; Scafidi J; Becher OJ; Saratsis AM; Hiner RL; Kambhampati M; Mariarita S; MacDonald TJ; Codispoti KE; Magge SN; Jaiswal JK; Packer RJ; Nazarian J
Oncotarget; 2015 May; 6(14):12141-55. PubMed ID: 25987129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
